Emerald Biostructures, the Bainbridge Island, WA-based company that produces X-ray crystallography images of drug targets, said today it has formed a partnership with Cambridge, MA-based Forma Therapeutics. The multi-year deal covers multiple targets for cancer drugs that Forma is seeking to develop. Financial terms of the deal aren’t being disclosed, although it will provide salaries for multiple full-time employees at Emerald. I wrote last month about how Emerald escaped a potential bankruptcy with the help of Forma and some venture capitalists in Boston.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
